Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Data from more than 16,000 trial participants point to possible challenges with assessing and safely administering novel therapeutics among those with comorbidities—which may be present in as much as half of the patient population.

Comorbidity Burden Is Associated With Increased Adverse Events, DMT Discontinuation in MS Clinical Trials

In the CAVS-MS study, 19% of participants with atypical or radiological-only presentations met the 2024 McDonald Criteria for MS, enabling earlier treatment initiation.

Application of New McDonald MS Criteria Uncovers Portion of Atypical Individuals Potentially Eligible for Disease-Modifying Treatment

GFAP changes positively correlated with gadolinium-enhancing lesion volume (P = 0.18) and negatively with left ventricular volume (P = -0.19).

Improved GFAP Levels With Ozanimod Linked to Slower Relapsing MS Progression

The vice president and senior global program lead for Hematology and Cell Therapy at BMS gave clinical commentary on encouraging phase 1 findings of CD19-XT in progressive and relapsing multiple sclerosis.

NeuroVoices: Rosanna Ricafort, MD, on Early Promise of CAR T-Cell Therapy CD19-XT in Multiple Sclerosis

Attending Physician, Neuromuscular/General Neurology & Electromyography; Neuromuscular Education Director and Neuromuscular Section Head, Children’s Hospital of Philadelphia

Videos

The pediatric neurologist at Children’s Hospital of Philadelphia gave perspective on some of the main issues the clinical community is figuring out with gene therapies and their integration to clinical practice. [WATCH TIME: 3 minutes]

Clinically Relevant Challenges and Roadblocks of Gene Therapies for Muscular Dystrophies: John Brandsema, MD

Founder and Executive Director, Sumaira Foundation

The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]

A Patient’s Perspective on Progress and Challenges in NMOSD Treatment Advances: Sumaira Ahmed

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Amber Freed, founder of SLC6A1 Connect, shared her personal journey and advocacy efforts to raise awareness for SLC6A1, a rare genetic epilepsy, in honor of Rare Disease Day.

Rare Disease Day 2025: Transforming Challenges Into Action for SLC6A1

Staff neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed how the CALLIPER trial’s lower proportion of patients with gadolinium-enhancing lesions mirrors clinical practice more closely than other progressive MS trials. [WATCH TIME: 2 minutes]

Ways to Align Patient Characteristics of Progressive Multiple Sclerosis Trials With Clinical Reality: Robert J. Fox, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

ISC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Insomnia and Sleep Disorders in Primary Care Settings

Paul Doghramji, MD, FAAFP, provides insight on the use of current treatment modalities for insomnia and the management of sleep disorders in primary care clinics.

Paul Doghramji, MD, FAAFP, provides an overview of the prevalence of sleep disorders, including insomnia, in the primary care setting.

Prevalence of Sleep Disorders in Primary Care Clinics

Dr Paul Doghramji shares insight on reasons for the underdiagnosis of insomnia and the importance of treating sleep disorders concurrently with comorbidities.

Identification of Sleep Disorders in Primary Care Clinics

An expert in sleep medicine comments on approaching screening patients for insomnia or other sleep disorders in the primary care setting.

Screening for Sleep Disorders in Primary Care Clinics

Paul Doghramji, MD, FAAFP, discusses best practices for referring patients with sleep issues to a sleep specialist.

Patient Referrals for Sleep Disorder Management

Dr Paul Doghramji shares tips for communication with patients once an insomnia diagnosis has been made.

Approaching Patient Conversations for Sleep Disorder Management

An expert in sleep medicine provides insight on the use of traditional insomnia medications in patients as well as DORAs, and common challenges experienced with these treatment options.

Treatment Options for Insomnia

Paul Doghramji, MD, FAAFP, shares his personal experience with DORAs in clinical practice to manage insomnia and discusses treatment adherence with insomnia medications.

Using DORAs for the Treatment of Insomnia

Dr Paul Doghramji shares his approach to switching medications for the treatment of insomnia.

Treatment Adherence and Switching Treatments for Insomnia

An expert in sleep medicine highlights challenges in prescribing DORAs and importance of discussing insomnia with patients in the primary care setting.

Access and Treatment of Insomnia in Primary Care Clinics

Clinical

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Prevalence of Sleep Disorders in Primary Care Clinics

EP: 1.Prevalence of Sleep Disorders in Primary Care Clinics

EP: 2.Identification of Sleep Disorders in Primary Care Clinics

EP: 3.Screening for Sleep Disorders in Primary Care Clinics

EP: 4.Patient Referrals for Sleep Disorder Management

EP: 5.Approaching Patient Conversations for Sleep Disorder Management

EP: 6.Treatment Options for Insomnia

EP: 7.Using DORAs for the Treatment of Insomnia

EP: 8.Treatment Adherence and Switching Treatments for Insomnia

EP: 9.Access and Treatment of Insomnia in Primary Care Clinics